Strongyloidiasis medical therapy: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Strongyloidiasis}} | {{Strongyloidiasis}} | ||
{{CMG}} | {{CMG}} ; {{AE}} {{ADG}} | ||
==Overview== | ==Overview== | ||
Revision as of 13:19, 21 June 2017
|
Strongyloidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Strongyloidiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Strongyloidiasis medical therapy |
|
Risk calculators and risk factors for Strongyloidiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
The drug of choice for the treatment of uncomplicated strongyloidiasis is ivermectin with albendazole as the alternative. All patients who are at risk of disseminated strongyloidiasis should be treated.[1]
Treatment
Antimicrobial Regimen
- Strongyloides stercoralis
- Preferred regimen: Ivermectin 200 mcg/kg/day PO qd for 2 days or two doses 2 weeks apart from each other[2]
- Alternative regimen: Albendazole 400 mg PO bid for 3-7 days[3]
References
- ↑ http://www.dpd.cdc.gov/dpdx/HTML/Strongyloidiasis.htm
- ↑ "WGO Practice Guideline Management of Strongyloidiasis" (PDF).
- ↑ Archibald LK, Beeching NJ, Gill GV, Bailey JW, Bell DR (1993). "Albendazole is effective treatment for chronic strongyloidiasis". Q J Med. 86 (3): 191–5. PMID 8483992.